Poly(2-methacryloyloxyethyl phosphorylcholine) for protein conjugation

Area of Science:

• Biomaterials Science
• Polymer Chemistry
• Protein Engineering

Background:

• Poly(2-methacryloyloxyethyl phosphorylcholine) (PMPC) is a biocompatible, zwitterionic polymer.
• PMPC forms a more compact conformation in aqueous solution than poly(ethylene glycol) (PEG).
• PEGylation is a common method to improve therapeutic protein pharmacokinetics.

Purpose of the Study:

• To evaluate PMPC for protein conjugation and assess its impact on therapeutic protein pharmacokinetics.
• To compare PMPC-protein conjugates with PEG-protein conjugates and native proteins.
• To investigate the potential of PMPCylation as an alternative or complementary strategy to PEGylation.

Main Methods:

• Conjugation of PMPC to interferon-alpha2a (IFN) using a bis-thiol specific derivative.
• Evaluation of in vitro antiviral and antiproliferative activity of PMPC-IFN.
• Pharmacokinetic studies in vivo to determine absorption and elimination half-lives.
• Western blot analysis to assess antibody binding resistance.

Main Results:

• PMPC-IFN conjugates demonstrated resistance to antibody binding.
• In vitro antiviral and antiproliferative activities were comparable to PEG-IFN.
• PMPC-IFN exhibited significantly extended absorption and elimination half-lives compared to native IFN and PEG-IFN.
• The compact conformation of PMPC contributed to an improved depot effect and slower tissue migration.

Conclusions:

• PMPCylation is a viable strategy for enhancing the pharmacokinetic properties of therapeutic proteins.
• PMPC-IFN conjugates show potential for improved therapeutic efficacy due to prolonged circulation time.
• PMPCylation offers a promising alternative or complement to PEGylation for protein drug development.